Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for advanced melanoma? T3011 trial launches

NCT ID NCT06214156

First seen Jan 15, 2026 · Last updated May 18, 2026 · Updated 25 times

Summary

This study tests a new drug, T3011, in 42 people with advanced melanoma that has spread. The main goals are to check safety and see if tumors shrink. Participants must have measurable tumors and be well enough for daily activities. This is an early-phase trial, so the focus is on safety and initial effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, China

    Contact

  • Chengdu Shangjin Nanfu Hospital

    RECRUITING

    Chengdu, China

    Contact

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, China

    Contact

  • Jilin Cancer Hospital

    RECRUITING

    Changchun, China

    Contact

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Zhongshan, China

    Contact

  • The First Affiliated Hospital of Bengbu Medical College

    RECRUITING

    Bengbu, China

    Contact

  • The Third People's Hospital of Zhengzhou

    RECRUITING

    Zhengzhou, China

    Contact

Conditions

Explore the condition pages connected to this study.